Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-22T15:43:02.271Z Has data issue: false hasContentIssue false
  • English
  • Français

Myth: Intravenous amiodarone is safe in patients with atrial fibrillation and Wolff–Parkinson–White syndrome in the emergency department

Published online by Cambridge University Press:  21 May 2015

Marius A. Tijunelis  and
Mel E. Herbert
Marius A. Tijunelis
Affiliation:
Clinical Emergency Medicine, KECK USC School of Medicine, Department of Emergency Medicine, LAC+USC Medical Center, Los Angeles County, Los Angeles, Calif.
Mel E. Herbert*
Affiliation:
Clinical Emergency Medicine, KECK USC School of Medicine, Department of Emergency Medicine, LAC+USC Medical Center, Los Angeles County, Los Angeles, Calif.
*
[email protected]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Wolff–Parkinson–White (WPW) syndrome with atrial fibrillation (AF) is a potentially life-threatening problem requiring rapid conversion to sinus rhythm. The most recent American Heart Association guidelines for the treatment of patients with WPW, published in conjunction with the 2000 Advanced Cardiac Life Support (ACLS) guidelines, suggests that intravenous amiodarone is a first-line therapy for AF–WPW; however the evidence suggests this is a potentially dangerous myth.

Keywords

amiodaronecardiac arrestarrythmiaWolff–Parkinson–White syndromeWPW
Type
Medical Mythology • Mythes médicaux
Information
Canadian Journal of Emergency Medicine , Volume 7 , Issue 4 , July 2005 , pp. 262 - 265
Copyright
Copyright © Canadian Association of Emergency Physicians 2005

References

1.Wolff, L, Parkinson, J, White, PD. Bundle-branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia. Am Heart J 1930;5:685–704.CrossRefGoogle Scholar
2.Gaita, F, Giustetto, C, Riccardi, R, Brusca, A. Wolff-Parkinson-White syndrome: identification and management. Drugs 1992;43:185–200.CrossRefGoogle ScholarPubMed
3.Newman, BJ, Donoso, E, Fridberg, CK. Arrhythmias in the Wolff-Parkinson-White syndrome. \Prog Cardiovasc Dis 1966; 9:147–65.CrossRefGoogle ScholarPubMed
4.Campbell, RWF, Smith, RA, Gallagher, JJ, Pritchett, ELC, Wallace, AG. Atrial fibrillation in the Preexcitation Syndrome. Am J Cardiol 1977;40:514–20.CrossRefGoogle ScholarPubMed
5.Klein, GJ, Bashore, TM, Sellers, TD, Pritchett, EL, Smith, WM, Gallagher, JJ. Ventricular fibrillation in the Wolff-Parkinson-White Syndrome. N Engl J Med 1979;301:1080–5.Google Scholar
6.Montoya, PT, Brugada, P, Smeets, J, Talajic, M, Della Bella, P, Lezaun, R, et al.Ventricular fibrillation in the Wolff-Parkinson-White syndrome. Eur Heart J 1991;12:144–50.Google ScholarPubMed
7.Pappone, C, Santinelli, V, Manguso, F. Augello, G, Santinelli, O, Vicedomini, G, et al.A randomized study of prophylactic catheter ablation in asymptomatic patients with the Wolff-Parkinson-White Syndrome. N Engl J Med 2003;349: 803–21.Google Scholar
8.Al-Khatib, SM, Pritchett, ELC. Clinical features of Wolff-Parkinson-White Syndrome. Am Heart J 1999;138:403–13.CrossRefGoogle ScholarPubMed
9.Chung1, KY, Walsh, TJ, Massie, E. Wolff-Parkinson-White syndrome. Am Heart J 1965;69:116–33.Google Scholar
10.Guidelines 2000 for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care (70-2041). Part 6: advanced cardiovascular life support: section 7: algorithm approach to ACLS emergencies: section 7A: principles and practice of ACLS. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation 2000; 102(8 suppl):I136–9.Google Scholar
11.Williams, EM Vaughan. A classification of antiarrythmic actions reassessed after a decade of new drugs [review]. J Clin Pharmacol 1984;24(4):129–47.CrossRefGoogle Scholar
12.Desai, AD, Chun, S, Sung, RJ. The role of intravenous Amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997;127:294–303.Google Scholar
13.Wellens, HJJ, Brugada, P, Abdollah, H, Dassen, WR. A Comparison of the electrophysiologic effects of intravenous and oral Amiodarone in the same patient. Circulation 1984;69:120–4.Google Scholar
14.Sellers, TD Jr, Campbell, RW, Bashore, TM, Gallagher, JJ. Effects of procainamide and quinidine sulfate in the Wolff-Parkinson-White syndrome. Circulation 1977;55(1):15–22.CrossRefGoogle ScholarPubMed
15.Sheinman, BD, Evans, T. Acceleration of ventricular rate by amiodarone in atrial fibrillation associated with the Wolff-Parkinson-White syndrome. Br Med J 1982;285:999–1000.CrossRefGoogle ScholarPubMed
16.Schutzenberger, WS, Leisch, F, Gmeiner, R. Enhanced accessory pathway conduction following intravenous amiodarone in atrial fibrillation: a case report. Int J Cardiol 1987;16:93–5.Google Scholar
17.Sulke, AN, Holt, P, Sowton, GE. Acceleration of conduction within an accessory pathway with propafenone. Int J Cardiol 1990;28(1):105–7.Google Scholar
18.Pastor, A, Almendral, JM, Ormaetxe, J, Arenal, A, Martínez-Al-day, J, Villacastín, J, et al.Ventricular fibrillation during treatment of atrial fibrillation with intravenous amiodarone in patients with the WPW syndrome [abstract]. Eur Heart J 1993;14 (suppl):294.Google Scholar
19.Boriani, G, Biffi, M, Frabetti, L, Azzolini, U, Sabbatani, P, Bronzetti, G, et al.Ventricular fibrillation after intravenous amiodarone in Wolff-Parkinson-White syndrome with atrial fibrillation. Am Heart J 1996;131:1214–6.Google Scholar